Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial
Background The IMpassion050 (NCT03726879) primary analysis showed similar pathologic complete response (pCR) rates with/without the addition of neoadjuvant atezolizumab to pertuzumab, trastuzumab, and chemotherapy in high-risk human epidermal growth factor receptor 2-positive early breast cancer in the intention-to-tre...